CFDE Data Portal | Search LOC105372126

	Label	Description
	LOC105372126 Gene (Entity type)	ENSG00000267284 - uncharacterized LOC105372126
	GSE196343 metformin 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE115542 digoxin 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE95077 amiloride 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE229663 GSE229666 menin inhibition 3 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE238018 MXRA8 knockout MDA-MB-231 3 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 cisplatin 3 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE103567 EZH2 inhibition 5 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE172494 nicotinamide 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE252944 AKT inhibition 11 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS

LOC105372126

ENSG00000267284 - uncharacterized LOC105372126

GSE196343 metformin 1 v 0 human dn

A Gene Set from LINCS

GSE115542 digoxin 2 v 0 human up

A Gene Set from LINCS

GSE95077 amiloride 1 v 0 human up

A Gene Set from LINCS

GSE229663 GSE229666 menin inhibition 3 v 2 human up

A Gene Set from LINCS

GSE238018 MXRA8 knockout MDA-MB-231 3 v 2 human dn

A Gene Set from LINCS

GSE216043 cisplatin 3 v 4 human up

A Gene Set from LINCS

GSE103567 EZH2 inhibition 5 v 2 human up

A Gene Set from LINCS

GSE172494 nicotinamide 3 v 1 human dn

A Gene Set from LINCS

GSE252944 AKT inhibition 11 v 0 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.